Triazole antifungal agents drug–drug interactions involving hepatic cytochrome P450

Abstract

Introduction: Triazole antifungal agents are often prescribed as first-line therapy for candidemia, in non-neutropenic hosts and invasive pulmonary aspergillosis, and in critically ill patients who receive many concomitant medications. As substrates and inhibitors of cytochrome P450 (CYP), the triazoles can interact with many drugs, which may lead to enhanced toxicity of the concomitant medication(s) or ineffective antifungal treatment. Therefore, clinicians must understand the drug interaction profile of this class.

Areas covered: This manuscript reviews the role of human hepatic CYP in triazole–drug interactions, illustrates how recent discoveries in pharmacogenetics and triazole metabolism impact our understanding of these interactions, and summarizes the most clinically important triazole–drug interactions. A search of English language, original research and scholarly reviews describing interactions between triazole antifungal agents and human CYP published from 1980 to present was undertaken using PubMed.

Expert opinion: Triazoles interact with many drugs and the primary mechanism for these interactions is hepatic CYP. Many studies published in the past 2 decades characterize these interactions using the state-of-the-art methods of the time. However, advances in genotyping, improved analytical technology and bioanalytical methods, which enable accurate molecular identification and stereochemical analysis, have substantially added to the understanding of the role hepatic CYP plays in triazole–drug interactions in humans.

Keywords:

• CYP
• CYP polymorphisms
• drug metabolism
• fluconazole
• itraconazole
• posaconazole
• triazole antifungals
• voriconazole

Notes

This box summarizes key points contained in the article.